Neeraj Agarwal, MD

Articles

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 6th 2021

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Dr. Agarwal on the Design of the AMPLITUDE Trial in mCSPC

September 24th 2021

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Dr. Agarwal on the Significance of the LATITUDE Trial in Metastatic CSPC

February 2nd 2021

Neeraj Agarwal, MD, discusses the significance of the phase 3 LATITUDE trial, which examined abiraterone acetate in patients with metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Remaining Challenges With Abiraterone in mCSPC

December 21st 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Remaining Challenges in mCSPC

December 11th 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC

August 4th 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Dr. Agarwal on the Progression of the COSMIC-021 Trial in mCRPC

July 29th 2020

Neeraj Agarwal, MD, discusses the rationale for the expansion of cohort 6 in the COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

June 29th 2020

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Dr Agarwal on the Rationale for ​Novel Combination​ ​Therapies in ​mCRPC

June 24th 2020

Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer​.

Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC

May 19th 2020

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Agarwal on Data With Cabozantinib/Atezolizumab in mCRPC

May 7th 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

April 29th 2020

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on PFS2 Data From the TITAN Trial in mCSPC

April 9th 2020

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

March 31st 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on Impact of the TITAN Trial With Apalutamide Plus ADT in mCSPC

March 18th 2020

Neeraj Agarwal, MD, discusses the impact of the TITAN trial in metastatic castration-sensitive prostate cancer.

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

March 17th 2020

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

February 27th 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on Drug Development in Metastatic Castration-Sensitive Prostate Cancer

February 12th 2020

Neeraj Agarwal, MD, discusses the need for further drug development in metastatic castration-sensitive prostate cancer.